Soleus Capital Master Fund, L.P. → ESSA Pharma Inc.

Stake: 9.80% Shares: 4,362,026 CUSIP: 29668H708 Class: Common Stock

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 10/100

Passive Schedule 13G filer baseline
High conviction ownership stake (9.8%)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

4 13D/G filings on this issuer

3 other filings besides this one

Filer Track Record

5 filings by this filer

4 other filings in the data moat

Short Interest

—

Not in latest FINRA snapshot

Other 13D/G Filings on ESSA Pharma Inc.

Filed	Form	Filer	Stake	Shares
2022-01-12	SC	Clarus Lifesciences III, L.P.	—	—	view →
2019-07-15	SC	EVENTIDE ASSET MANAGEMENT, LLC	—	—	view →
2019-01-11	SC	Clarus Lifesciences III, L.P.	—	—	view →

Other Filings by Soleus Capital Master Fund, L.P.

Filed	Form	Issuer	Stake	Shares
2026-08-31	SCHEDULE 13G	Evolus, Inc.	—	—	view →
2026-06-18	SCHEDULE 13G	BIODESIX INC BDSX	—	—	view →
2026-05-27	SCHEDULE 13G	INSPIRE MEDICAL SYSTEMS, INC. INSP	—	—	view →
2025-04-11	SCHEDULE	Theratechnologies Inc.	10.40%	4,801,375	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →